Tuesday, June 18, 2024

Prognostic Signatures Compared for ER-Positive Breast Cancer

ROR, BCI, EPclin are significantly more prognostic for recurrence for women with node-negative disease

TUESDAY, Feb. 20, 2018 (HealthDay News) — For women with node-negative early endocrine receptor (ER)-positive breast cancer, the PAM50-based Prosigna risk of recurrence (ROR), Breast Cancer Index (BCI), and EndoPredict (EPclin) provide the most prognostic information, according to a study published online Feb. 15 in JAMA Oncology.

Ivana Sestak, Ph.D., from Queen Mary University of London, and colleagues conducted a within-patient comparison of the prognostic value of six multigene signatures in 774 postmenopausal women with early ER-positive breast cancer who received endocrine therapy for five years. The prognostic value of the Oncotype Dx recurrence score, ROR, BCI, EPclin, Clinical Treatment Score, and four-marker immunohistochemical score was compared.

The researchers found that the ROR, BCI, and EPclin provided the most prognostic information (hazard ratios, 2.56, 2.46, and 2.14, respectively). Each of these provided significantly more information than the Clinical Treatment Score, recurrence score, and four-marker immunohistochemical score (hazard ratios, 1.99, 1.69, and 1.95, respectively). For the 183 patients with one to three positive nodes, substantially less information was provided by all six molecular tests; more additional prognostic information was provided by the BCI and EPclin than the other signatures.

“These data might help oncologists and patients to choose the most appropriate test when considering chemotherapy use and/or extended endocrine therapy,” the authors write.

Several authors disclosed financial ties to the biotechnology and pharmaceutical industries, and one author is an inventor on the EPclin patent.

Abstract/Full Text (subscription or payment may be required)

Copyright © 2018 HealthDay. All rights reserved.

the authorHealthDay.com